You are here

SBIR Phase I: Bioluminescence Resonance Energy Transfer Assays for Clinical Chemistry

Award Information
Agency: National Science Foundation
Branch: N/A
Contract: 0711621
Agency Tracking Number: 0711621
Amount: $99,993.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: BT
Solicitation Number: NSF 06-598
Timeline
Solicitation Year: 2006
Award Year: 2007
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
25 Bear Paw UAMS/BioVentures
san jose, CA 95138
United States
DUNS: 171080885
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Daniel Sobek
 DPhil
 (650) 515-7897
 daniel_sobek@zymera.com
Business Contact
 Daniel Sobek
Title: DPhil
Phone: (650) 515-7897
Email: daniel_sobek@zymera.com
Research Institution
N/A
Abstract

This Small Business Innovation Research (SBIR) Phase I research project aims to develop a point-of-care assay for creatine kinase, an important toxicity biomarker, to screen for adverse drug reactions (ADRs) using whole blood. The assay will utilize bioluminescent resonance energy transfer (BRET) probes incorporating quantum dots. The proposed technology is likely to impact toxicity testing, allowing physicians to test for potential ADR at an early stage and take corrective measures. With over 50% of Medicare patients taking multiple medications, the probability of ADRs is high and any inexpensive and reliable test for toxicity would be of benefit to these individuals and society as a whole.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government